Effectiveness of guideline-recommended cardiac drugs for reducing mortality in the elderly medicare heart failure population: A retrospective, survey-weighted, cohort analysis

Drugs and Aging

Volumn 27, Issue 10, 2010, Pages 845-854

  Richardson, Diane M ^a   Bain, Kevin T ^b   Diamond, James J ^c   Novielli, Karen D ^c   Lee, Seina P ^d   Goldfarb, Neil I ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b excelleRx Inc   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Johnson and Johnson Pharmaceutical Services   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

ACE inhibitors, therapeutic use; Angiotensin II receptor antagonists, therapeutic use; Beta adrenergic receptor antagonists, therapeutic use; Elderly; Heart failure, treatment; Mortality.

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEMOGRAPHY; DRUG EFFICACY; ELDERLY CARE; FEMALE; HEALTH CARE SURVEY; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; CARDIOVASCULAR AGENTS; COHORT STUDIES; GUIDELINE ADHERENCE; HEART FAILURE; HUMANS; MEDICARE; TREATMENT OUTCOME; UNITED STATES;

EID: 77957729794     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11539340-000000000-00000     Document Type: Article

References (41)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statis-tics Subcommittee. Circulation 2008; 117 (4): e25-146
2. Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence ofheart failure in elderly persons, 1994-2003. Arch Intern Med 2008; 168 (4): 418-24
3. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Up-date the 2001 Guidelines for the Evaluation and Manage-ment of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the Inter-national Society for Heart and Lung Transplantation; en-dorsed by the Heart Rhythm Society. Circulation 2005; 112 (12): e154-235
4. American College ofClinical Pharmacy, Cheang KI, Ott C, et al. Research in women and special populations. Pharmacotherapy 2008; 28 (9): 93e-113e
5. Dore DD, Larrat EP, Vogenberg FR. Principles ofepidemiology for clinical and formulary management profes-sionals. Pharmacy Therapeutics 2006; 31 (4): 218-26
6. Eppig FJ, Chulis GS. Matching MCBS (Medicare Current Beneficiary Survey) and Medicare data: the best of both worlds. Health Care Financ Rev 1997; 18 (3): 211-29
7. Eppig FJ, Edwards B. Computer matching of Medicare Current Beneficiary Survey data with Medicare claims. Health Survey Research Methods Conference Proceedings; 1995 Jun 24-26; Hyattsville (MD): National Center for Health Statistics. DHHS Pub. No. (PHS). 1996: 96-1013
8. Centers for Disease Control and Prevention. Classification ofdiseases, functioning, and disability [online]. Available from URL: http://www.cdc.gov/ nchs/icd.htm [Accessed 2010 Aug 16]
9. GoffJr DC, Pandey DK, Chan FA, et al. Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project. Arch Intern Med 2000; 160 (2): 197-202
10. Lee DS, Donovan L, Austin PC, et al. Comparison ofcoding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care 2005; 43 (2): 182-8
11. Birman-Deych E, Waterman AD, Yan Y, et al. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 2005; 43 (5): 480-5
12. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40 (5): 373-83
13. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45 (6): 613-9
14. Bang H, Robins JM. Doubly robust estimation in missing data and causal inference models. Biometrics 2005; 61 (4): 962-73
15. Curtis LH, Hammill BG, Eisenstein EL, et al. Using inverse probability-weighted estimators in comparative effective-ness analyses with observational databases. Med Care 2007; 45 (10 Suppl. 2): S103-7
16. Luzier AB, DiTusa L. Underutilization of ACE inhibitors in heart failure. Pharmacotherapy 1999; 19 (11): 1296-307
17. The Large State Peer Review Organization Consortium. Heart failure treatment with angiotensin-converting en-zyme inhibitors in hospitalized Medicare patients in 10 large states. Arch Intern Med 1997; 157 (10): 1103-8
18. The CONSENSUS Trial Study Group. Effects ofenalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316 (23): 1429-35
19. Pfeffer MA, Braunwald E, Moye LA, et al. Effect ofcaptopril on mortality and morbidity in patients with left ven-tricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327 (10): 669-77
20. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect oframipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence ofheart failure. Lancet 1993; 342 (8875): 821-8
21. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333 (25): 1670-6
22. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353 (9146): 9-13
23. MERIT-HF Study Group. Effect ofmetoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised in-tervention trial in congestive heart failure. Lancet 1999; 353 (9169): 2001-7
24. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITEII. Lancet 2000; 355 (9215): 1582-7
25. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362 (9386): 759-66
26. Ng TM, Carter O, Guillory GS, et al. High-impact articles related to the pharmacotherapeutic management of systolic heart failure. Pharmacotherapy 2004; 24 (11): 1594-633
27. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ven-tricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33 (7): 1948-55
28. Hood S, Taylor S, Hemingway H. Older patients and advances in cardiology. Lancet 1997; 350 (9093): 1779-80
29. Cleland JG. ACE inhibitors for the prevention and treatment of heart failure: why are they 'under-used'? J Hum Hypertens 1995; 9 (6): 435-42
30. Scheiner MA, Kimmel SE. Heart failure and angiotensin-converting enzyme inhibitors: is there a need for specialty care? J Gen Intern Med 1997; 12 (9): 581-2
31. McMurray JJ. Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? Eur Heart J 1998; 19 Suppl. L: L15-21
32. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestiveheartfailure. NEngl JMed 1991; 325 (5): 293-302
33. The SOLVD Investigators. Effect ofenalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327 (10): 685-91
34. Stuart B, Simoni-Wastila L, Zuckerman I, et al. Medication use by aged and disabled Medicare beneficiaries across the spectrum of morbidity: a chartbook [online]. Available from URL: http://www.pharmacy.umaryland.edu/lamy [Accessed 2007 Dec 26]
35. Fisher ES, Whaley FS, Krushat WM, et al. The accuracy of Medicare's hospital claims data: progress has been made, butproblemsremain. AmJPublicHealth 1992; 82(2): 243-8
36. Toprol-XL (metoprolol succinate extended-release tablets) [package insert]. Wilmington (DE): AstraZeneca LP, 2009 Feb
37. Coreg (Carvedilol tablets) [package insert]. Durham (NC): GlaxoSmithKline, 2008 Apr
38. Andrus MR, Loyed JV. Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pul-monary disease and cardiovascular co-morbidity: safety issues. Drugs Aging 2008; 25 (2): 131-44
39. Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: nonselective beta-and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2004; 44 (3): 497-502
40. Ormiston TM, Salpeter SR. Beta-blocker use in patients with congestive heart failure and concomitant obstructive airway disease: moving from myth to evidence-based practice. Heart Fail Monit 2003; 4 (2): 45-54
41. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007; 49 (2): 171-80